


BD solutions for enabling delivery of complex biologics

# BD Neopak™ XtraFlow™ Glass Prefillable Syringe



**BD Neopak™ XtraFlow™ Glass Prefillable Syringe** solution leverages 8 mm needle length in combination with thin wall cannula to **reduce pressure drop** and **enhance flow**.



## Experience

- BD partnering in combination product development with the biopharmaceutical industry for 30 years<sup>4</sup>
  - XtraFlow™ needle technology is built on BD Neopak™ Glass Prefillable Syringe technology
    - Compatible with existing manufacturing and inspection technologies/practices
    - Supports single PFS platform\* approach
- \* PFS platform: Serving a range of requirements (silicone reactivity, drug fill volume, viscosity, device integration, etc.) with a minimal number of SKUs and little to no change in core materials (glass, silicone, rubber, etc.)

## Availability

- BD Neopak™ XtraFlow™ Glass Prefillable Syringe is a product under development
- Samples for both 1 mL & 2.25 mL formats are available

## Key benefits

Improving subcutaneous drug delivery and end-user injection experience<sup>13</sup>

- **Reduce injection force** and/or **time** for a fixed solution viscosity<sup>12</sup>  
 Ejection force or injection time required to push on the plunger rod for viscous solution delivery (10-30Cp) is reduced by up to 57%\*<sup>2</sup>

- **Positively impact patient preference**<sup>3</sup>  
 64% of self-injecting chronic disease patients preferred the BD Neopak™ XtraFlow™ (27G 8mm UTW). Reduced injection force was the main reason given followed by the shorter needle length<sup>3</sup>
- **Reduce intramuscular injection risk by 2.5x to 13x**<sup>3μ†</sup>
- **Reduce needle-related anxiety**<sup>3†</sup>

\* When compared to 12.7 mm special thin wall needle

μ With BD Neopak™ XtraFlow™ 27G 8 mm ultra-thin wall when compared to the BD Neopak™ 12.7 mm 27G special-thin wall syringe  
 Ejection force and injection time values were simulated through a mathematical model based on the Hagen-Poiseuille equation

† In case of a non-recommended subcutaneous injection technique (45° or 90° angle with no skin pinch) as simulated by mathematical model

‡ When compared to BD Neopak™ 12.7mm 27G special-thin wall syringe



## References

1. Injection time and ejection force calculation [internal study], Le Pont-de-Claix, France; Becton, Dickinson and Company, 2020
2. BD Neopak™ XtraFlow™ 2.25 mL prototype evaluation [internal study] , Le Pont-de-Claix, France; Becton, Dickinson and Company, 2020
3. Pager et al. (2020), "User experience for manual injection of 2 mL viscous solutions is enhanced by a new prefillable syringe with staked 8 mm ultra-thin wall needle" Expert Opinion on Drug Delivery, <https://doi.org/10.1080/17425247.2020.1796630>  
\* When compared to 12.7 mm special thin wall needle
4. BD Medical Pharmaceutical Systems\_BD Hypak™ Glass Prefillable Syringe since 1975\_BD Website

### BD Medical

Pharmaceutical Systems

#### United States

1 Becton Drive

Franklin Lakes, NJ 07417

+1 800 225 3310

#### Europe

11 rue Aristide-Bergès

38800 Le Pont-de-Claix

France

Phone: +33 4 76 68 36 36 - Fax: +33 4 76 68 35 05

Becton Dickinson France S.A.S - Share capital: 64 719 915 €

RCS Grenoble B 056 501 711

**bd.com**

